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Introduction
The primary and secondary prevention of various
thromboembolic events increasingly entail novel oral
anticoagulation agents (NOACs), but warfarin is still
the drug of choice for patients with valvuloplasty and
especially in developing countries because of its
perceived cost-effectiveness. Warfarin's optimal
management presents a challenge to physicians
because of its narrow therapeutic index, variable dose
response, multi-factorial interactions and the need for
adequate monitoring.1 To deal with this challenge,
Western countries have devised strategies and
recommendations such as dedicated anti-coagulation
clinics, patient self-monitoring, computer
programmes and using NOACs.2
Monitoring of patients on warfarin is usually done by
international normalized ratio (INR) of prothrombin
time (PT) and the quality of anti-coagulation assessed
by a linearly interpolated percent time in therapeutic
range (TTR) as an intermediate outcome.3 A TTR of less
than 60% has been found to confer no apparent benefit
of warfarin therapy over anti-platelet therapy against
thromboembolic events.4
A few multi-centre studies have established meantime
in therapeutic range across geographic regions
representing mostly Western populations with some
Eastern/Asian participation; ranging from 77% in the
Swedish population, 64% in the United States
population to 49% and 36% in the Indian population.5,6
Such low TTRs in Asians can be attributed to multiple
factors, including ethnicity/genetics,7 limited resources
and poor infrastructure for adequate monitoring of
warfarin anti-coagulation.8
Limited studies from Pakistan have assessed quality of
anti-coagulation using INR within target range as a
quality measure for warfarin anti-coagulation.9,10
However, these studies do not specify the use of one of
the most extensively studied methods of determining
TTR- the Rosendaal method.1 The current study was
planned to evaluate the quality of warfarinisation of
patients employing TTR determination according to the
Rosendaal method.11
Patients and Methods
This retrospective chart review was conducted at Aga
Khan University Hospital (AKUH), Karachi, and
comprised data of patients on warfarin anti-coagulation
with INR testing for 1st year of treatment related to the
period from January 2013 to April 2015. The records
were identified through the international classification
of diseases version 9 (ICD 9) coding system maintained
by the AKUH health information management
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Objective: To assess the time in therapeutic range in patients on warfarin anti-coagulation therapy.
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department Ethical approval was taken from
institutional ethics review committee. Sample size was
calculated using Epi tool online software with an
assumed population standard deviation of 23.34,6
confidence interval (CI) of 95% and desired precision of
5. Based on these calculations, we set a sample size of
100. Non-probability convenience sampling was used.
Patient characteristics, including demographics,
anthropometrics and clinical data, recorded from
medical charts. INR values and dates of INR testing were
obtained from computer records of the AKUH
laboratory only. Patients with less than 2 consecutive
INR values after start of warfarin anti-coagulation, INR
testing intervals of more than 56 days in the first 3
months of warfarin anti-coagulation, and patients
already on warfarin for more than 3 months previously
were excluded.
TTR of the subjects was determined and so was the
percentage of patients on warfarin anticoagulation with
a mean TTR <60%. Also, factors associated with TTR
values were determined and mean TTR of patients
across all 4 quarters (3 month time periods) for the 1st
year after therapy were compared. The association of
TTR with composite outcome; defined as all outcomes
whether major / minor bleeding and thromboembolic
events combined, was also explored. Thromboembolic
events were defined as any episode of thrombosis or
ischemia in any system. Bleeding events included major
and minor bleeding events combined. Major bleeding
was defined as any bleeding requiring transfusion
and/or symptomatic bleeding in a critical area,
including intracranial bleeds, and minor bleeding was
defined as any bleeding not covered under the
definition of major bleeding.
Descriptive statistics were used to explain
demographic and general measures, including
measures for central tendency and dispersion.
Individual percentage time in therapeutic range (iTTR)
was calculated using the Rosendaal method11 for each
patient. This method uses linear interpolation to assign
an INR value to each day between successive observed
INR values. Gaps of 56 days or more between INR
values were not interpolated as it is traditionally
understood to indicate a lack of monitoring, and a
period across which iTTR is not interpolated. After
interpolation, the percentage of time during which the
interpolated INR values lie between the specified
target range (2.0-3.0 or 2.5-3.5) was calculated. TTR was
also calculated for each patient during the4 quarters
and compared. Percentage of patients with TTR <60%
was calculated as well.
For comparison of TTR between two groups, 2 tailed t-
test was used. For comparison of TTR among 3 or more
groups, one-way analysis of variance (ANOVA) or
Kruskal-Wallis test, as appropriate, was used. For
relationship of continuous independent variables with
TTR, linear regression analysis was performed. Logistic
regression analysis was performed to identify risk
factors for TTR <60% and assess relationship of TTR with
outcomes. For comparison of TTR between quarters,
repeated measures Friedman's ANOVA was used.
Threshold of significance was set at p<0.05.
Results
Of the 1141 patient files reviewed, 92(8%) were
included. Of the 1049 cases excluded, 356(34%) had
only 1 INR value, 534(52%) had less than 3 months
follow-up, and 159(15%) were already on warfarin for
more than 3 months previously. 
Most common indication was deep vein thrombosis
(DVT) 24(26%). 
A Total 1214 INR Tests were performed, with a median
of 11 (inter-quartile range [IQR]: 6-17) tests per
patient. Median INR tests in range were 31.1% (IQR:
23.1-47.7) and the median time in therapeutic range
(TTR) was 34.9% (IQR: 20.0-55.7) while the median
extended TTR (INR 1.8 to 3.5) was 60.6% (IQR: 37.8-
80.0). Median total time below therapeutic range
(TBTR) was 38.9% (IQR: 19.8-67.9) with percentage
time below INR 1.5 (increased thrombotic risk) of 5.9%
(IQR: 0.1-20.3). Median time above therapeutic range
(TATR) was 8.3% (IQR: 0.2-26.9) with median total time
above INR 4.5 (increased haemorrhagic risk) of 0.0%
(IQR: 0.0-2.9). Overall, 71(77.2%) patients had iTTR
below 60% (Table-1). 
Observing patient TTR according to INR target range
showed that 86(93.5%) patients had target INR between
2.0 and 3.0, with a mean TTR of 40.5±23.6% compared
to 6(6.5%) patients in the target INR group between 2.5-
3.5who had mechanical prosthetic heart valves with
mean TTR of 15.7±14.8% (p=0.013). Furthermore,
70(75.6%) patients with target INR range of 2-3 had TTR
<60% and all 6(6.5%)patients with target INR range of
2.5-3.5 had TTR <60% (p=0.330).
Multiple regression analysis predicted iTTR) with
number of co-morbids contributing significantly to the
prediction model (p<0.0005) (Table-2).
Logistic regression model to ascertain the relationship
of predictors with TTR <60% was statistically significant
(p=0.000008). The model explained 41.2% (Nagelkerke
R2) variance in TTR<60% and correctly classified 81.5%
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cases. Sensitivity was 52.4% and specificity was 90.1%
with positive predictive value (PPV) of 61.1% and
negative predictive value (NPV) of 86.5%. Of all the
predictors, only the number of co-morbids was
statistically significant (p<0.05).
TTR<60% was statistically significant with composite
outcome (p<0.05). Increasing TTR was associated with a
reduction in likelihood of composite outcome, and
TATR significant with an increase in likelihood of
composite outcome and bleeding events (p<0.05).
Comparison between the four quarters was done after
excluding 24(26%) DVT cases as they had a median
follow-up time of 125 (IQR: 83.25-174.5). There was no
significant difference across all 4 quarters for TTR or
percentage of patients with TTR <60% (p>0.05).
Furthermore, 50% (34) patients were lost to follow-up
by the start of the 4th quarter which further increased
to 48(70.6%) by the end of the year (Table-4).
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Table-1: Baseline Characteristics of Patients.
                                                                                                       Population                                                 TTR %                                        P-value                                    TTR<60%                              P-value
                                                                                                            N = 92                                           Median (IQR) or                                                                           (% within group)
                                                                                                  Median (IQR) or                                      Mean (±SD)
                                                                                             (% within category)                                              
Gender                                                                                                                                                                                                                             .077‡                                        33(75.0%)                                .634c2
Male                                                                                                44 (47.8%)                                           43.5%(±24.2)                                                                                       38(79.2%)                                       
Female                                                                                            48 (52.2%)                                           34.6% (±23.1)                                                                                                                                                  
Age(years)                                                                                     56 (36-71)                                                                                                                                                                                                                           
<35                                                                                                  18(19.6%)                                        30.7% (14.7-55.9)                                .274*                                        14(77.8%)                                .447**
35-65                                                                                              42 (45.7%)                                        45.3% (27.3-61.2)                                                                                   30(71.4%)                                       
>65                                                                                                 32 (34.8%)                                        31.7% (19.7-41.8)                                                                                   27(84.4%)                                       
BMI                                                                                             26.7 (23.4-31.0)                                                                                                       .711*                                         3(60.0%)                                 .843**
Underweight (<Below 18.5)                                                     5(5.4%)                                           48.3% (16.5-63.4)                                                                                   21(80.8%)                                       
Normal (18.5 – 24.9)                                                                 26(28.3%)                                      31.9% (15.5 – 50.9)                                                                                 27(77.1%)                                       
Overweight (25.0 – 29.9 )                                                        35(38.0%)                                        39.4% (27.5-55.8)                                                                                   20(76.9%)                                       
Obese (>30.0)                                                                             26(28.3%)                                      32.6% (22.3 – 55.4)                                                                                                                                             
Co-Morbids                                                                                                                                                               N/A                                                N/A                                                N/A                                          N/A
Hypertension                                                                                45(48.9%)                                                                                                                                                                                                                           
Diabetes Mellitus                                                                        31 (33.7%)                                                                                                                                                                                                                          
Ischaemic Heart Disease                                                           18(19.6%)                                                                                                                                                                                                                           
Dyslipidaemia                                                                                 5 (5.4%)                                                                                                                                                                                                                             
Cancer                                                                                               7 (7.6%)                                                                                                                                                                                                                             
Chronic Kidney Disease                                                                4(4.3%)                                                                                                                                                                                                                             
Psychiatric Illnesses                                                                      2(2.2%)                                                                                                                                                                                                                             
Others                                                                                              20(21.7%)                                                                                                                                                                                                                           
Indication                                                                                                                                                                                                                       .135~                                                                                            .159**
Deep Venous Thrombosis                                                         24(26.1%)                                            44.4%(±27.6)                                                                                       16(66.7%)                                       
Atrial Fibrillation (non-valvular)                                            22(23.9%)                                            33.9%(±16.8)                                                                                       19(86.4%)                                       
Atrial Fibrillation (valvular)                                                        3(3.3%)                                                32.1(±37.7)                                                                                          2(66.7%)                                        
Mechanical Prosthetic Heart Valves                                        9(9.8%)                                              32.4%(±29.3)                                                                                        7(77.8%)                                        
Pulmonary Embolism                                                                   8(8.7%)                                              37.2%(±14.8)                                                                                        7(87.5%)                                        
Hypercoagulable States                                                               9(9.8%)                                              63.5%(±22.2)                                                                                        4(44.4%)                                        
Mesenteric Thrombosis                                                                6(6.5%)                                              33.1%(±19.8)                                                                                        5(83.3%)                                        
Cerebral Venous Sinus                                                                 3(3.3%)                                                20.1(±19.7)                                                                                           3(100%)                                         
Thrombosis                                                                                      8(8.7%)                                                31.1(±15.8)                                                                                           8(100%)                                         
Others                                                                                                                                                                                                                                                                                                                                             
Specialty Monitoring Anticoagulation                                                                                                                                                                                                                                                                                 
Anticoagulation Clinic                                                                        36                                                    41.4%(±27.6)                                    .425‡                                        27(75.0%)                                .159c2
Others                                                                                                      56                                                    37.2%(±21.3)                                                                                       44(88.6%)                                       
‡ - Independent T-test, c2 - Pearson Chi-square, * -Kruskal-Wallis Test,   ** -Fisher's Exact Test, 
~ - Welch ANOVA. All p values < 0.05 are significant.
BMI: Body mass index.
TTR: Time in therapeutic range.
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Table-2: Summary of Multiple regression analysis of predictors for iTTR.
                                                                                    Population                                             TTR %                                   P-value                                    B                                     S.E.                                  Beta
                                                                                         N = 92                                        Median (IQR) or
                                                                               Median (IQR) or                                  Mean (±SD)
                                                                          (% within category)                                          
Intercept                                                                                                                                                                                           < 0.0005                              54.762                              5.854
Number of Co-Morbids                                                                                                                                                                                                                                                                                                              
No Co-Morbids                                                                                                                                                                                < 0.0005                             -11.882                             1.899                                -0.568
1                                                                                     26(28.3%)                                        55.0%(±25.8)                                                                                                                                                                         
2                                                                                     20(21.7%)                                        44.8%(±21.9)                                                                                                                                                                         
3                                                                                     24(26.1%)                                        31.4%(±18.7)                                                                                                                                                                         
                                                                                       22(23.9%)                                        22.4%(±12.8)                                                                                                                                                                         
Length of Follow-Up                                       198 (108-329) days                                             -                                             0.122                                   0.034                               0.022                                0.162
Interval of INR Testing                                  18.7(10.0-28.1) days                                            -                                             0.303                                  -0.194                               0.187                                -0.123
Number of Invalid Intervals                                                                                                                                                                                                        -2.273                               4.036                                -0.073
0                                                                                     43(46.7%)                                         38.5%(±3.5)                                 0.575                                                                                                                               
1                                                                                     36(39.1%)                                         41.1%(±4.5)                                                                                                                                                                          
2                                                                                     11(12.0%)                                         33.0%(±5.6)                                                                                                                                                                          
3                                                                                        2(2.2%)                                            39.5%(±5.2)                                                                                                                                                                          
B=unstandardized regression coefficient, SE = standard error of the coefficient, Beta= standardized coefficient.
All p values < 0.05 are significant.
TTR: Time in therapeutic range. iTTR: Individual percentage time in therapeutic range.
Table-3: Correlation of Outcomes with TTR, TTR<60%, TATR and TBTR.
                                                                          No Outcome          Composite Outcome         Thromboembolic Events          Bleeding Events          Major Bleeding            Minor Bleeding
Population (N=92)                                         77(83.7%)                         15(16.3%)                                       4(4.3%)                                      9(9.8%)                             5(5.4%)                              4(4.3%)
TTR<60% (N=71)                                          56(78.9%)                      15(21.1%)* a                                   4(5.6%)*                                   9(12.7%)*                         5(7.0%)*                            4(5.6%)*
TTR¤                                                                       39.40%                              27.5%¤                                           14.60%                                       31.20%                             17.50%                               32.80%
                                                                             (21.8-61.2)                        (12.8-32.1)                                    (12.3-24.7)                                (13.9-43.4)                      (10.3-43.5)                        (31.2-48.3)
Time Below Therapeutic Range¤                  18.90%                              18.90%                                           61.30%                                       11.80%                               6.40%                                17.20%
                                                                              (6.4-65.7)                          (6.4-65.7)                                     (47.9-77.0)                                 (3.2-22.6)                           (0-50.4)                           (10.8-24.5)
Time Above Therapeutic Range                    42.70%                              42.7%¤                                           24.90%                                       49.0%¤                             57.00%                               45.90%
                                                                             (22.2-57.0)                        (22.2-57.0)                                     (7.6-29.6)                                 (40.2-66.6)                      (22.4-83.0)                        (38.9-50.4)
* - Fischer's Exact Test, significant at p=.019
¤Logistic Regression analysis revealed-
-TTR significant with composite outcome (c2 (1) =5.498, p=0.019).
-Time above therapeutic range significant with composite outcome (c2 (1) =16.514, p=0.000048).
-Time above therapeutic range significant with Bleeding Events (c2 (1) =16.809, p=0.000041).
All p values < 0.05 are significant.
TTR: Time in therapeutic range
TATR: Time above therapeutic range. TBTR: Time below therapeutic range.
Table-4: Comparison of TTR and TTR<65% across the 4 quarters.
Quarters                                                                       Population (N = 68)                                                          Median TTR¤ %(IQR)                                                                       TTR<60% (N=20§)
1st quarter                                                                                 68(100%)                                                                             27.8(12.5-51.8)                                                                                         18(90.0%)
2nd quarter                                                                               44(64.7%)                                                                             38.8(14.5-67.6)                                                                                         12(60.0%)
3rd quarter                                                                                34(50.0%)                                                                             37.9(17.6-60.3)                                                                                         14(70.0%)
4th quarter                                                                                23(33.8%)                                                                             46.7(19.5-80.3)                                                                                         13(65.0%)
µ - Friedmann test was not significant, p value = .056
§ - Cochran's Q Test was not significant, Exact P value = 0.134
All p values < 0.05 are significant.
TTR: Time in therapeutic range. IQR: Interquartile range.
Discussion
Our cohort of patients on warfarin therapy had aTTR of
34.9% according to Roosendaal method which is among
the lowest reported TTR in literature even for Southeast
Asia.6 Furthermore, 77.2% of our patients had a TTR of less
than 60% denoting no benefit of warfarin therapy over
anti-platelets.4
The number of co-morbids was the only factor that
statistically explained poor anti-coagulation. In contrast
to other studies, neither patient level factors such as
gender, age and BMI had any association with TTR in our
cohort nor did any treatment level characteristics. Our
results showed a median of 11 INR tests per patient and
18-day interval between consecutive tests with an IQR of
6-17 and 10-28 days respectively. These IQRs have more
variation compared to vitamin K antagonism for
prevention of stroke and embolism trial in atrial
fibrillation (ROCKET-AF) results which showed IQR of 18-
34 for INR tests per patient and IQR of 19-25 days for
interval between 2 consecutive INR tests, which might be
contributing to our poorer TTR, although this was not
proven statistically in our cohort.6
Even though 53.3% patients had at least 1 invalid interval,
number of invalid intervals had no association with TTR
which is again in contrast with literature.12 This could be
attributed to small sample size and the overall poor TTR in
our sample. There was no statistically significant
difference in TTR between anti-coagulation monitoring
and other clinics contrary to the experience of European
countries.2
Patients mostly remained below therapeutic range 38.9%
of the time and above therapeutic range only 8.3% of the
time which is similar to the trend seen in ROCKET-AF.6
However, 4.3% of patients experienced thromboembolic
events while 9.3% experienced bleeding events,
suggesting our population was not only at a higher risk of
developing adverse outcomes, but also at a higher risk of
bleeding events with even below therapeutic range TTR
on warfarin. These results expose the unique challenges
in achieving adequate warfarinisation in Asian
populations which go beyond infrastructure constraints
and affordability issues. The traditional preference for
adopting multitude of herbal remedies along with
contemporary treatment may pose a significant but
particularly difficult-to-account-for challenge for the
treating physician in terms of unexpected drug-drug
interactions.13 The varied dietary patterns and thus
fluctuations in dietary vitamin K intake also make dose
prediction uncertain.13,14
Furthermore, genetics / ethnicity along with geographical
location independently determine the level of
warfarinisation being achieved.7,14 Due to the
unavailability of routine genetic testing in our setup, the
effect of pharmacogenetics on our results could not be
taken into account. 
TTR and TATR had significant association with outcomes
in our study as established in literature.3 All 15 patients
with adverse outcomes had TTR less than 60%.No
significant difference between different quarters was
found in our patients unlike other studies which showed
an improving TTR over time for patients on warfarin
therapy.6,15
Our study had a significant dropout rate which not only
contributed to poor TTR but also skewed our results. We
could not assess the factors behind this loss of follow-up
due to our study design. Hence, further studies need to be
done to evaluate these factors and strategies need to be
devised to improve regular follow-up in our setup.
Although definite conclusion cannot be drawn due to
relatively small sample size, the data of this cohort does
show that patients have very poor anti-coagulation with
warfarin and that strategies such as anti-coagulation
clinics do not improve these outcomes even in a tertiary
care hospital setup in Pakistan. Therefore, an alternative
option could be to encourage the use of NOACs which do
not require regular monitoring, have lesser interactions
compared to warfarin, and provide equivalent protection
to warfarin even with lower levels of compliance.16 The
barrier to NOACs in our country is the cost which needs to
be addressed by cost-effective local manufacturing of
these newer anti-coagulation agents as suggested in
literature.17
Conclusion
The average TTR of patients on anti-coagulation with
warfarin was poor which corroborates with the trend seen
in literature. Considering the myriad of factors at play in
the background, ranging from cost and infrastructure
constraints to pharmacology of warfarin, it might be
prudent to look at NOACs as first choice for anti-
coagulation in the developing world.
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